Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on August 26, 2020, to report the entry into a Material Definitive Agreement. The Company is listed on The Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
This filing details a public equity offering rather than operational financial results. Key transaction metrics include:
- Shares Issued: 14,285,715 shares of common stock.
- Offering Price: $1.05 per share.
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to 2,142,857 additional shares.
- Expected Net Proceeds: Approximately $13.5 million (base) or $15.6 million (if over-allotment is fully exercised).
- Underwriting Fees: 7.5% underwriting discount plus 1% management fee of gross proceeds.
- Other Expenses: Non-accountable expense allowance of $50,000, up to $90,000 in legal fees, and $12,900 in clearing expenses.
The filing text does not provide current revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change is the execution of an Underwriting Agreement with H.C. Wainwright & Co., LLC, dated August 26, 2020. The closing of the Offering is expected on or about August 31, 2020. This transaction represents a significant capital raise intended to fund the Company's operations.
Guidance, Outlook, and Restrictions
Lock-Up Period: The Company agreed not to sell any shares of common stock or securities convertible into or exercisable for common stock for 90 days following the closing of the Offering, subject to limited exceptions and the Underwriter's written consent.
Regulatory Status: The shares are being offered pursuant to an effective Form S-3 registration statement declared effective by the SEC on May 13, 2020.
The filing does not contain specific operational guidance, risk factors beyond standard underwriting terms, or management commentary on future clinical or commercial milestones.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected August 31, 2020) and the actual net proceeds received.
- Confirm whether the Underwriter exercised the over-allotment option for the additional 2,142,857 shares.
- Review the final prospectus supplement filed on August 27, 2020, for updated use of proceeds.
- Monitor the Company's cash position post-closing to assess runway for ongoing operations.